Brain-volume increase with sustained remission in patients with treatment-resistant unipolar depression

Journal of Clinical Psychiatry

Volumn 73, Issue 5, 2012, Pages 625-631

  Phillips, Jennifer L ^a   Batten, Lisa A ^a   Aldosary, Fahad ^a   Tremblay, Philippe ^a   Blier, Pierre ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CAPSULA INTERNA; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DSM-IV; FEMALE; FOLLOW UP; GRAY MATTER; HUMAN; INFERIOR TEMPORAL GYRUS; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; ORBITAL CORTEX; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; TREATMENT RESPONSE; VOXEL BASED MORPHOMETRY; WHITE MATTER;

EID: 84861829390     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m06865     Document Type: Article

References (39)

1. Koolschijn PCMP, van Haren NEM, Lensvelt-Mulders GJLM, et al. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp. 2009;30(11):3719-3735. doi:10.102/hbm.20801 PubMed
2. Dwivedi Y, Rizavi HS, Conley RR, et al. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003;60(8):804-815. doi:10.101/archpsyc.60.8.804 PubMed (Pubitemid 36960912)
3. aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ. 2009;180(3):305-313. doi:10.1503/cmaj.080697 PubMed
4. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15(11):7539-7547. PubMed
5. Russo-Neustadt AA, Beard RC, Huang YM, et al. Physical activity and antidepressant treatment potentiate the expression of specific brain-derived neurotrophic factor transcripts in the rat hippocampus. Neuroscience. 2000;101(2):305-312. doi:10.1016/S0306-452(0)0349-3 PubMed
6. Sairanen M, O'Leary OF, Knuuttila JE, et al. Chronic antidepressant treatment selectively increases expression of plasticity-related proteins in the hippocampus and medial prefrontal cortex of the rat. Neuroscience. 2007;144(1):368-374. doi:10.1016/j.neuroscience.206.08.069 PubMed (Pubitemid 44839045)
7. Lu B, Gottschalk W. Modulation of hippocampal synaptic transmission and plasticity by neurotrophins. Prog Brain Res. 2000;128:231-241. doi:10.1016/S079-6123(0)28020-5 PubMed (Pubitemid 35461239)
8. Bremner JD, Randall P, Scott TM, et al. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry. 1995;152(7):973-981. PubMed
9. MacQueen GM, Campbell S, McEwen BS, et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci U S A. 2003;100(3):1387-1392. doi:10.1073/pnas.0374810 PubMed (Pubitemid 36184011)
10. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160(8):1516-1518. doi:10.176/api.ajp.160.8. 1516 PubMed (Pubitemid 41070930)
11. Frodl TS, Koutsouleris N, Bottlender R, et al. Depression-related variation in brain morphology over 3 years: effects of stress? Arch Gen Psychiatry. 2008;65(10):1156-1165. doi:10.101/archpsyc.65.10.156 PubMed
12. Li CT, Lin CP, Chou KH, et al. Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study. Neuroimage. 2010;50(1):347-356. doi:10.1016/j.neuroimage.209.1.021 PubMed
13. Yucel K, McKinnon M, Chahal R, et al. Increased subgenual prefrontal cortex size in remitted patients with major depressive disorder. Psychiatry Res. 2009;173(1):71-76. doi:10.1016/j.pscychresns.208.07.013 PubMed
14. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649-659. doi:10.1016/S06-323(03)0231-2 PubMed (Pubitemid 39658481)
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
16. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp.134.4.382 PubMed (Pubitemid 9136500)
17. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971;9(1):97-113. doi:10.1016/028-3932(71)9067-4 PubMed
18. Szegedi A, Jansen WT, van Willigenburg APP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344-353. doi:10.408/JCP.07m03780 PubMed
19. Blier P. Medication combination and augmentation strategies in the treatment of major depression. In: Stein DJ, Kupfer DJ, Schatzberg AF, eds. The American Psychiatric Publishing Textbook of Mood Disorders. Arlington, VA: American Psychiatric Publishing; 2006.
20. Smith SM, De Stefano N, Jenkinson M, et al. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr. 2001;25(3):466-475. doi:10.1097/04728-201050-02 PubMed (Pubitemid 32440803)
21. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23(suppl 1):S208-S219. doi:10.1016/j.neuroimage.204.07.051 PubMed (Pubitemid 39421720)
22. Ashburner J, Friston KJ. Voxel-based morphometry: the methods. Neuroimage. 2000;11(6, pt 1):805-821. doi:10.106/nimg.20.0582 PubMed
23. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38(1):95-113. doi:10.1016/j.neuroimage.207.07.07 PubMed (Pubitemid 47440133)
24. Worsley KJ, Andermann M, Koulis T, et al. Detecting changes in nonisotropic images. Hum Brain Mapp. 1999;8(2-3):98-101. doi:10.102/(SICI)1097- 0193(19)8:2/3〈98:AID-HBM5〉3.0.CO;2-F PubMed (Pubitemid 29480295)
25. Mori S, Wakana S, Nagae-Poetscher L, et al. MRI Atlas of Human White Matter. Amsterdam, The Netherlands: Elsevier; 2005.
26. Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol. 2009;19(7):457-465. doi:10.1016/j. euroneuro.209.01.015 PubMed
27. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281-288. doi:10.176/api.ajp.209.09020186 PubMed
28. Fava M. Augmentation and combination strategies for complicated depression. J Clin Psychiatry. 2009;70(11):e40. doi:10.408/JCP.801tx13c PubMed
29. Moore GJ, Bebchuk JM, Wilds IB, et al. Lithium-induced increase in human brain grey matter. Lancet. 2000;356(9237):1241-1242. doi:10.1016/S0140-6736(0) 02793-8 PubMed
30. Sassi RB, Nicoletti M, Brambilla P, et al. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett. 2002;329(2):243-245. doi:10.1016/S0304-3940(02)0615-8 PubMed (Pubitemid 34880083)
31. Garver DL, Holcomb JA, Christensen JD. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol Psychiatry. 2005;58(1):62-66. doi:10.1016/j.biopsych.205.02.08 PubMed (Pubitemid 40909937)
32. Drevets WC. Orbitofrontal cortex function and structure in depression. Ann N Y Acad Sci. 2007;1121(1):499-527. doi:10.196/anals.1401.029 PubMed
33. Zou K, Huang X, Li T, et al. Alterations of white matter integrity in adults with major depressive disorder: a magnetic resonance imaging study. J Psychiatry Neurosci. 2008;33(6):525-530. PubMed
34. Gutman DA, Holtzheimer PE, Behrens TEJ, et al. A tractography analysis of two deep brain stimulation white matter targets for depression. Biol Psychiatry. 2009;65(4):276-282. doi:10.1016/j.biopsych.208.09.021 PubMed
35. Frodl T, Jäger M, Smajstrlova I, et al. Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J Psychiatry Neurosci. 2008;33(5):423-430. PubMed
36. Frodl T, Meisenzahl EM, Zetzsche T, et al. Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J Clin Psychiatry. 2004;65(4):492-499. doi:10.408/JCP. v65n0407 PubMed
37. Vythilingam M, Vermetten E, Anderson GM, et al. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry. 2004;56(2):101-112. doi:10.1016/j.biopsych.204.04.02 PubMed (Pubitemid 38844785)
38. Hunsberger J, Austin DR, Henter ID, et al. The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin Neurosci. 2009;11(3):333-348. PubMed
39. Enzinger C, Fazekas F, Matthews PM, et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology. 2005;64(10):1704-1711. doi:10.1212/01.WNL.0161871.83614.B PubMed (Pubitemid 40695802)